Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neonatal Abstinence Syndrome: full-pipeline trial registry
2 of 18 indexed Neonatal Abstinence Syndrome trials are currently recruiting.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 2 currently recruiting · #953 of 28,707 conditions by registered trial count
Neonatal Abstinence Syndrome: 18 US clinical trials tracked, 2 recruiting.
Neonatal Abstinence Syndrome is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is T. John Winhusen, PhD, running 3 of these trials.
Enrollment posture brief
Registry condition neonatal-abstinence-syndrome
OPEN 2 | RECR 11% | LATE 5 | EARLY 4 | RANK #953 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Heart Failure (11% recruiting · 9 trials)
Neonatal Abstinence Syndrome lists 2 open slots (11% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neonatal Abstinence Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neonatal Abstinence Syndrome is recruiting below its size-band peers.
2 of 18 indexed trials (11.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neonatal Abstinence Syndrome research.
T. John Winhusen, PhD accounts for 3 of 18 trials (16.7%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Neonatal Abstinence Syndrome trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 18 trials that report a genuine target (sentinel values excluded). 16 of those (88.9%) plan for fewer than 100 participants.
-
Neonatal Abstinence Syndrome research is mostly interventional.
14 interventional and 4 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
An Intervention Mapping Approach to Closing the Gap in Maternal OUD and Infant NAS Care (SUPPORT)
University of Pennsylvania
NCT06576323
MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome
Milton S. Hershey Medical Center
NCT05937594
Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy
The Cooper Health System
NCT03092011
Neurostimulation to Improve NOWS Outcomes
Spark Biomedical
NCT05129020
A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants
Yale University
NCT04419857
Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women
Washington State University
NCT04783558
Medication Treatment for Opioid Use Disorder in Expectant Mothers
T. John Winhusen, PhD
NCT03918850
Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain
Henrietta Bada
NCT03396588
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
T. John Winhusen, PhD
NCT03911466
RCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants
University of Pittsburgh
NCT02178189
Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome
National Institute on Drug Abuse (NIDA)
NCT00510016
Role of Low Lactose Infant Formula In The Management of Neonatal Abstinence Syndrome
MetroHealth Medical Center
NCT03549936
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
T. John Winhusen, PhD
NCT03911739
Buprenorphine for the Treatment of Neonatal Abstinence Syndrome
Thomas Jefferson University
NCT00521248
MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study
Boston Medical Center
NCT03718104
Treatment of Neonatal Abstinence Syndrome
Eastern Maine Medical Center
NCT01723722
Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome
Indiana University
NCT04298853
Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines
Thomas Jefferson University
NCT01671410
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 2 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Neonatal Abstinence Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neonatal Abstinence Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neonatal Abstinence Syndrome page
18 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Neonatal Abstinence Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- T. John Winhusen, PhD sponsors the most Neonatal Abstinence Syndrome trials on record, review their full trial history before evaluating a specific study. See T. John Winhusen, PhD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neonatal Abstinence Syndrome condition card totals 18 registered trials; most-linked intervention Buprenorphine Sublingual Product; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.